Souhaitez-vous accéder aux communiqués récents ?

Basel, March 28, 2018 - Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting,...

Preis stellt für Novartis einen attraktiven Wert dar Verkaufserlös wird in Übereinstimmung mit den Prioritäten für die Kapitalallokation verwendet, einschliesslich für Bolt-on-Akquisitionen Verkauf...

Price reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best long-term...

Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on a...

EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients   Results demonstrate...

Tasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA...

Collaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline  Teams will explore the development of...

Bertrand Bodson, Chief Digital Officer, est nommé au Comité de direction de Novartis (Executive Committee of Novartis, ECN) Steffen Lang, Global Head Novartis Technical Operations, est nommé à l'ECN ...

Bertrand Bodson, Chief Digital Officer, wird in die Geschäftsleitung von Novartis berufen Steffen Lang, Global Head Novartis Technical Operations, wird in die Geschäftsleitung von Novartis berufen ...

Bertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN Shannon Klinger...